Divergent Histology in Bladder Cancer: What We Need to Know?
UroCancer Clinics of India · 2024
DOI: 10.4103/ucci.ucci_14_24 ↗Kurz gefasst
Fachartikel in der Zeitschrift UroCancer Clinics of India, 2024. Verfasst von Shashank Agrawal und 2 weiteren Autor:innen. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
The 2022 WHO classification of urinary tract tumors identifies several less common subtypes of invasive urothelial carcinoma, all of which are classified as high-grade. Reporting the percentage of divergent differentiation or specific subtypes is recommended whenever feasible. The role of neoadjuvant and adjuvant chemotherapy in these histologies is still uncertain, as prospective data are limited. This chapter emphasizes the histologic traits of divergent differentiation and bladder cancer subtypes outlined in the latest WHO classification, along with updates on their clinical characteristics.
Zitieren
APA
Agrawal, S., Menon, A. R., & Pooleri, G. K. (2024). Divergent Histology in Bladder Cancer: What We Need to Know?. UroCancer Clinics of India. https://doi.org/10.4103/ucci.ucci_14_24
Vancouver
Agrawal S, Menon AR, Pooleri GK. Divergent Histology in Bladder Cancer: What We Need to Know?. UroCancer Clinics of India. 2024. doi:10.4103/ucci.ucci_14_24
BibTeX
@article{Agrawal2024,
author = {Agrawal, Shashank and Menon, Arun Ramdas and Pooleri, Ginil Kumar},
title = {Divergent Histology in Bladder Cancer: What We Need to Know?},
journal = {UroCancer Clinics of India},
year = {2024},
doi = {10.4103/ucci.ucci_14_24}
}
EUVIMED